Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
et al., 2021, Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer, British Journal of Cancer, ISSN:0007-0920
et al., 2021, The Oxford Classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers, Clinical Cancer Research, ISSN:1078-0432
et al., 2021, Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression, Journal for Immunotherapy of Cancer, Vol:9, ISSN:2051-1426
et al., 2020, Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography, European Journal of Nuclear Medicine and Molecular Imaging, ISSN:0340-6997, Pages:1-15
et al., 2020, Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using 18F-Fluorothymidine Positron Emission Tomography, The Journal of Nuclear Medicine, Vol:61, ISSN:0161-5505, Pages:1743-1748